Endobronchial Ultrasound Biopsy Market Trends

Statistics for the 2023 & 2024 Endobronchial Ultrasound Biopsy market trends, created by Mordor Intelligence™ Industry Reports. Endobronchial Ultrasound Biopsy trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Trends of Endobronchial Ultrasound Biopsy Industry

The Cancer Diagnosis Segment is Expected to Hold a Significant Share in the Market During the Forecast Period

The main indications of endobronchial ultrasound (EBUS) include primary diagnosis, staging, and restaging of lung cancer. The cancer segment is expected to register a significant growth rate during the forecast period owing to the rising burden of lung cancer worldwide, the rising adoption of endobronchial ultrasound biopsy for cancer diagnosis and increasing technological advancements.

The increasing prevalence of lung cancer is a significant driver for EBUS use in diagnosis and staging. The rising burden of lung cancer cases is expected to propel the market's growth. For instance, according to the American Cancer Society (ACS) Cancer Statistics 2024, 2 million new cancer cases are expected to be diagnosed in the United States in 2024, compared to 1.9 million in 2023. Out of the total cancer cases, 234.5 thousand new cases are estimated to be lung and bronchus cancer in 2024. EBUS offers a minimally invasive way to obtain tissue samples compared to traditional surgical biopsies. Therefore, the rising lung cancer cases in the region are expected to propel the demand for endobronchial ultrasound biopsy as it is a minimally invasive procedure that can be performed using local anesthesia and moderate sedation.

Furthermore, newer EBUS bronchoscopes boast improved image quality, allowing for more precise visualization of lung structures and abnormalities. This leads to better targeting of biopsy sites and a higher diagnostic yield. For instance, according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), in 2024, EUBS allows for earlier detection of lung cancer by reaching peripheral lung lesions that might be missed by other methods. It also helps in staging cancer, which is crucial for treatment planning. Therefore, it is reported that EBUS biopsy is an important method of diagnosis, and staging of the lung is useful in lung cancer.

Additionally, the rising launches of innovative endobronchial ultrasound biopsy devices by market players are contributing significantly to the market growth. For instance, in October 2023, Praxis Medical, a medical device company, received approval from the FDA for its EndoCore endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) fine needle biopsy device. This is a significant advancement in the diagnosis of lung cancer and other lung diseases, and it is expected to develop and market innovative devices during the forecast period.

Therefore, owing to the aforementioned factors, such as the rising burden of cancer, increasing adoption of endobronchial ultrasound biopsy, and new product launches by market players, the segment is expected to register a significant growth rate during the forecast period.

Endobronchial Ultrasound Biopsy Market: New Lung & Bronchus Cancer Cases (in Thousand), By Sex, United States, 2024

North America is Expected to Cover a Large Share of the Market During the Forecast Period

North America is expected to hold a significant market share in the endobronchial ultrasound biopsy market owing to factors such as the high burden of lung cancer and other respiratory diseases, such as COPD and TB, rising research and development spending on disease diagnostics, and the high concentration of market players in the region.

The increasing number of respiratory diseases in Canada drives the demand for minimally invasive EBUS technology. According to the Canadian Cancer Society's May 2022, it was estimated that 30 thousand Canadians would be diagnosed with lung and bronchus cancer, representing 13% of new cancer cases in 2022. Also, a research study published in Biosystems Journal in January 2022 used Electronic Medical Record (EMR) data from primary care clinics in seven provinces across Canada to develop predictive models to identify COPD in the Canadian population. The study stated that approximately 10% of Canadians aged 35 years or older were living with COPD. Therefore, the high burden of such diseases is expected to propel the demand for EBUS biopsy for the early and effective diagnosis of such diseases, which is expected to propel the market's growth in the region.

Furthermore, according to the Condition and Disease Categories (RCDC), in the May 2024 update, the spending on R&D in the United States for COPD was USD 148 million in 2023, USD 595 million in 2023 for tuberculosis, and USD 504 million for lung cancer in 2023. Therefore, the high spending on respiratory diseases research is expected to boost the development of innovative EBUS biopsy devices in the nation, which is further expected to augment the market's growth during the forecast period.

Therefore, the aforementioned factors, such as the high burden of respiratory diseases and government grants for R&D of various respiratory diseases, are expected to create opportunities for market players to accelerate the development of innovative biopsy devices in North America.

Endobronchial Ultrasound Biopsy Market - Growth Rate by Region

Endobronchial Ultrasound Biopsy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)